Abstract Gomisin A (GA) is an active ingredient of the fruits of Schisandra chinensis which has been widely used as a tonic in traditional Korean medicine. GA induces not only endothelium-dependent but also endotheliumindependent relaxation in an isolated rat's thoracic aorta. This study was aimed to investigate the molecular mechanism by which GA induces endothelium-independent vasorelaxation. Rat aortic rings were denuded of endothelium, mounted in organ baths, and subjected to contraction or relaxation. We measured the amount of GTP RhoA as well as the phosphorylation level of 20 kDa myosin light chains (MLC 20 ), myosin phosphatase-targeting subunit 1 (MYPT1) and protein kinase C-potentiated inhibitory protein for heterotrimeric myosin light-chain phosphatase of 17 kDa (CPI17). Pretreatment with GA dose-dependently inhibited the concentration-response curves in response to sodium fluoride (NaF) or thromboxane A 2 agonist U46619, but not to phorbol 12, 13-dibutyrate (PDBu). GA decreased the activation of RhoA as well as the phosphorylation level of MLC 20 , MYPT1 Thr855 , and CPI17 induced by 8.0 mM NaF or 30 nM U46619. However, K + channel blockers such as glibenclamide, apamin, or charybdotoxin did not affect the vascular relaxation induced by GA. Furthermore, GA did not affect the level of phosphorylation of CPI17 induced by PDBu. GA reduces vascular contraction through inhibition of RhoA/Rho-kinase pathway in endotheliumdenuded rat aorta.
Introduction
Gomisin A (GA) is a small molecular weight lignan contained in Fructus Schisandrae, the dried seed of Schisandra chinensis which is widely used as a health food product and a tonic in traditional Korean medicine (Park et al. 2007 ). S. chinensis have some beneficial effects including hepatoprotective, antioxidative, anti-inflammatory, anticancer, and anti-HIV actions (Chen et al. 1997; Chiu et al. 2002; Choi et al. 2006; Wu et al. 2003; Yasukawa et al. 1992) . The fruit of S. chinensis is known to be enriched with lignans (Nakajima et al. 1983) , of which schisandrin (2-9%), γ-schisandrin (1-5%), deoxyschisandrin (0.2-1.1%), and GA (0.7-3%) are major ingredients, depending on the plant origin and harvest season (percentage dry weight; He et al. 1997; Park et al. 2007) .
GA or an aqueous extract of S. chinensis induced not only endothelium-dependent but also endotheliumindependent vascular relaxation in isolated thoracic aorta through activation of nitric oxide (NO) pathway in endothelium or direct dephosphorylation of myosin light chains (MLC) in vascular smooth muscle (Park et al. 2007 ; Rhyu et al. 2006) . GA releases nitric oxide from endothelium through Ca 2+ -dependent activation and translocation of eNOS (Park et al. 2009a) . Moreover, the relaxation by GA in endothelium-denuded aortic rings was inhibited by calyculin, an inhibitor of MLC phosphatase, implicating involvement of RhoA/Rho-kinase signaling pathway which inhibits MLC phosphatase. The small guanosine triphosphatase (GTPase) RhoA plays an important role as a molecular switch in the enhancement of Ca 2+ sensitivity of smooth muscle contraction (Hirata et al. 1992) . The activation of RhoA leads to the subsequent activation of an effector, Rho-kinase (Leung et al. 1995) . Activation of Rho-kinase decreases the activity of myosin light-chain phosphatase (MLCP) through phosphorylation of myosin phosphatase-targeting subunit 1 (MYPT1) at Thr855 and CPI17 at Thr38, resulting in enhancement of vascular contractility (Somlyo and Somlyo 2003) . The RhoA/Rhokinase plays an important role in development of cardiovascular diseases such as heart failure, coronary artery disease, pulmonary hypertension, arteriosclerosis, restenosis, and stroke which show excessive activation of the RhoA/Rhokinase signaling pathway (Budzyn et al. 2006; Budzyn and Sobey 2007; Hirooka et al. 2004; Shimokawa and Takeshita 2005) . Recently the RhoA/Rho-kinase pathway has received attention as genetic disruption of the pathway blocks elevation of vascular tone under hypertensive condition without affecting regulation of the blood pressure (Wirth et al. 2008 ).
Here we investigated the mechanism by which GA inhibits vascular smooth muscle contraction. Therefore, the purpose of present study was to investigate the inhibitory effects of GA on RhoA activation and subsequent phosphorylation of MYPT1 or CPI17 and on vascular smooth muscle contraction induced by 11,9 epoxymethanoprostaglandin F 2α (U46619) or sodium fluoride (NaF). We also investigated the effects of K + channel blockers on vascular relaxation induced by GA.
Methods

Plant material
S. chinensis fruits were collected from Mungyeong, Korea in September 2005. A voucher specimen (accession number S. chinensis-PDRL-1) has been deposited in the Herbarium of Pusan National University (Park et al. 2009a ). S. chinensis was identified by our group (Professor Young Whan Choi).
Isolation of GA
The dried fruits of S. chinensis (2.0 kg) were ground to a fine powder and were extracted three times with n-hexane in the sonicator. The suspension was filtered, evaporated under reduced pressure at low temperature and lyophilized. The brown, oily residue of hexane extract (308 g) was obtained. The remnant was extracted again with chloroform and methanol sequentially to yield chloroform (14 g) and methanol extract fractions (1,368 g). The hexane extract (15.2 g) was evaporated in vacuo and chromatographed on a silica gel (40 m, J.T. Baker, NJ, USA) column (70× 8.0 cm) with a step gradient 0%, 5%, 10%, 20%, 30% ethyl acetate in hexane (each 1 L). The fraction 21 (800 mL, 600.5 mg) were separated on a silica gel column (100× 3.0 cm) with 5% acetone in CH 2 Cl 2 to give a GA (200 mL, 308 mg). Pure GA was identified by HPLC on a Phenomenex Luna C18 column (Phenomenex, 150 × 4.6 mm I.D.; 5-m particle size).
The chemical structure ( Fig. 1 ) of GA was verified by liquid chromatography-mass spectrometry (Bruker BioApex FT mass spectrometer) and NMR analysis (Bruker DRX 400 C, running gradients, and using residual solvent peaks as internal references (Ikeya et al. 1979) . Highresolution mass spectra were recorded on a Bruker FT mass spectrometer (Park et al. 2009a ).
Drugs
The drugs and chemicals were obtained from the following sources: NaF, U46619, phorbol 12,13-dibutyrate (PDBu), charybdotoxin (CTX), apamin (Apa), glibenclamide (GB), phenylephrine, and KCl from sigma chemicals (St. Louis, MO, USA). Stock solution of gomisin A, U46619, PDBu, and GB were prepared in dimethylsulfoxide (DMSO). Stock solution of Apa was prepared in 0.05 M acetic acid. All other reagents were analytical grade.
Organ bath study
The investigation was conducted in accordance with Guide for the Care and Use of Laboratory Animals (Institutional Review Board, Kyungpook National University School of Medicine). Male Sprague-Dawley rats, weighing 320-350 g, were used. With animals under anesthesia (sodium pentobarbital 50 mg kg −1 , i.p.), the thoracic aorta was immediately excised and immersed in an ice-cold, modified Krebs solution composed of (in millimolar) NaCl, 115.0; KCl, 4.7; CaCl 2 , 2.5; MgCl 2 , 1.2; NaHCO 3 , 25.0; KH 2 PO 4 , 1.2; and dextrose, 10.0. The aorta was cleaned of all adherent connective tissue on wet filter paper, soaked in the Krebs-bicarbonate solution and cut into four ring segments (4 mm in length) as described by Seok's method (Seok et al. 2006) . In order to investigate the direct effect of GA in vascular smooth muscle, the rings were denuded of endothelium by gently rubbing the internal surface with a forcep edge. Two stainless-steel triangles were inserted through each vessel ring. Each aortic ring was suspended in a water-jacketed organ bath (22 ml) maintained at 37°C and aerated with a mixture of 95% O 2 and 5% CO 2 . One triangle was anchored to a stationary support, and the other was connected to an isometric force transducer (Grass FT03C, Quincy, Mass., USA). The rings were stretched passively by imposing the optimal resting tension, 2.0 g, which was maintained throughout the experiment. Each ring was equilibrated in the organ bath solution for 90 min before the experiment involving the contractile response to 50 mM of KCl addition. Isometric contractions were recorded using a computerized data acquisition system (PowerLab/8SP, ADInstruments, Castle Hill, NSW, Australia). To determine the effect of GA on NaF, U46619 or PDBu were each added into organ baths to elicit tension 30 min after pretreatment with GA (0.1 mM, 0.3 mM, or 1.0 mM) or vehicle. The contractile responses to 8.0 mM NaF, 30 nM U46619 and 0.1 μM PDBu were recorded for 40, 15, and 40 min, respectively. To determine the effect of K + channel blockers, K + channel blockers were pretreated before vascular relaxation were induced by GA. GA or vehicle were added cumulatively to elicit relaxation when vascular contraction induced by phenylephrine (0.1 μM, 15 min), NaF (8.0 mM, 40 min) or U46619 (30 nM, 15 min) reached plateaus in endothelium-denuded rat aortic rings pretreated with GB (10 μM), Apa (500 nM), CTX (10 nM) or vehicle for 20 min.
SDS-PAGE for MYPT1 and CPI17
After completion of the functional study, muscle strips were quickly immersed in acetone containing 10% trichloroacetic acid (TCA) and 10 mM dithiothreitol (DTT) precooled to −80°C. The aortic rings were washed in acetone containing 5 mM DTT to remove TCA, airdried, and stored at −80°C until use. Previously stored samples were homogenized in a buffer containing 320 mM sucrose, 50 mM Tris, 1 mM EDTA, 1% Triton X-100, 1 mM DTT, and protease inhibitors leupeptin (10 μg ml −1 ), trypsin inhibitor (10 μg ml −1 ), aprotinin (10 μg ml −1 ), phenylmethylsulfonyl fluoride (PMSF; 100 μg ml −1 ), and the phosphatase inhibitor sodium orthovanadate (Na 3 VO 4 ; 2 mM). Protein-matched samples (Bradford assay) were electrophoresed (SDS-PAGE), transferred to nitrocellulose membranes, and subjected to an immunoblot with a p-MYPT1 antibody (1:4,000, Upstate Biotechnology, Lake Placid, NY, USA) and a p-CPI17 antibody (1:250, Santa Cruz Biotechnology, Inc) that detect phosphorylated MYPT1 and CPI17. Anti-rabbit IgG and anti-goat IgG, conjugated with horseradish peroxidase (HRP), were used as the secondary antibody (1:4,000, Sigma, St. Louis, MO, USA and 1:1,000, Santa Cruz Biotechnology, Inc). The nitrocellulose membranes were stripped of the p-MYPT1 and p-CPI17 antibody and reblotted with total MYPT1 antibody (1:4,000, BD Biosciences Pharmingen, San Diego, CA, USA) and CPI17 antibody (1:500, Upstate Biotechnology, Lake Placid, NY, USA). Anti-mouse IgG and anti-rabbit IgG conjugated with horseradish peroxidase were used as the secondary antibody (1:4,000, Sigma, St. Louis, MO, USA and 1:1,000, Upstate Biotechnology, Lake Placid, NY, USA). The bands containing p-MYPT1, p-CPI17, t-MYPT1, and t-CPI17 were visualized with enhanced chemiluminescence (ECL) on films, and then analyzed by a computer-assisted image analyzer (Labworks, version 4.5; UVP Inc., Upland, CA).
Urea-PAGE for MLC 20 phosphorylation
Muscle strips were quick frozen by immersion in acetone containing 10% TCA and 10 mM DTT precooled to −80°C. Muscles were washed four times with acetone containing 5 mM DTT for 15 min each to remove TCA and were soaked 60 min with frequent vortex in 100 μl of urea sample buffer containing 20 mM Tris base · 23 mM glycine (pH 8.6), 8.0 M urea, 1 M thiourea, 10 mM DTT, 10% glycerol and, 0.04% bromophenol blue. A 12.5% polyacrylamide gels containing 40% glycerol were preelectrophoresed for 30 min at 300 V. The running buffer consists of 20 mM Tris base/23 mM glycine (pH 8.6), 0.97 mM thioglycolate, and 0.97 mM DTT. The ureaextracted samples (12 μl) were electrophoresed at 300 V for 6 h, transferred to nitrocellulose membranes, and subjected to immunoblotting with a specific myosin light chain 20 antibody (1:2,000, Sigma, St. Louis, MO, USA). Antimouse IgM (goat), conjugated with horseradish peroxidase, was used as a secondary antibody (1:4,000, Assay design, Ann Arbor, MI, USA; Kim et al. 2004 ).The bands containing myosin light chains were visualized with ECL on films, and then analyzed by a computer-assisted image analyzer (Labworks, version 4.5; UVP Inc., Upland, CA).
Assay for RhoA activation
Muscle strips were quick frozen by liquid nitrogen, and kept at −80°C. The RhoA assay was performed as previously described (Seok et al. 2008) , the procedure followed the manufacture's protocol of G-LISA™ RhoA Activation Assay Biochem Kit™ (Cytoskelecton Inc, Denver, CO, USA). Briefly, previously stored samples were homogenized in a lysis buffer, and were centrifuged at 13,200 rpm for 15 min at 4°C. The resultant supernatants and equal volume of ice-cold binding buffer were added into each well for which 37 μg of proteins were loaded. The plate was shaken on a cold orbital microplate shaker (300 rpm) for 30 min at 4°C, flicked out of the solution from wells, and incubated with diluted anti-RhoA primary antibody followed by secondary antibodies on a microplate shaker (300 rpm) at room temperature for 45 min each. The plate was incubated with HRP detection reagent for 15 min at 37°C, after addition of HRP stop buffer, the absorbance was immediately recorded at 490 nm.
Statistical analysis
Data are expressed as mean ± SEM and were analyzed by repeated measures analysis of variance (ANOVA) for tension measurement and one-way ANOVA followed by Dunnett's test for biochemical studies. P values less than 0.05 were regarded as significant.
Results
Effect of GA on vascular contraction induced by NaF, U46619, or PDBu Thirty minutes after the pretreatment with GA or vehicle, the concentration-response relationships to NaF, U46619, or PDBu in endothelium-denuded aortic rings were obtained by means of a cumulative addition of the chemicals (Fig. 2) . The tension is expressed as a percentage to initial contractions in response to 50 mM KCl. Pretreatment with GA inhibited the contractile responses to U46619 or NaF, but not to PDBu, an activator of PKC. Maximum contraction (E max ) and EC 50 for the contractile responses to NaF or U46619 in vehicle and GApreconditioned rat aortic strips are shown in Table 1 Effect of K + channel blockers on vascular relaxation induced by GA Since opening of K + channels exert vascular relaxation, we investigated whether GA exerts vascular relaxation through opening of K + channels by using K + channel blockers. Although the vehicle did not affect vascular tension induced by phenylephrine, NaF, or U46619, GA produced vascular relaxation, which was not affected by pretreatment with glibenclamide, a blocker of ATP-sensitive K + channel (Fig. 3a) . In summary, pretreatment with GB (10 μM), Apa (500 nM), or CTX (10 nM) for 20 min did not affect vascular relaxation induced by GA (Fig. 3) .
Inhibitory effect of GA on vascular contraction and MLC 20 phosphorylation induced by NaF or U46619
In order to investigate whether GA relaxes vascular contraction through regulation of thick filament, we determined the level of MLC 20 phosphorylation. NaF and U46619 increased phosphorylation of MLC 20 to 40.7± 4.2% or 33.7±1.3%, respectively, in endothelium-denuded aortic rings. Treatment of rat aortic rings with 0.3 and 1.0 mM GA significantly decreased the phosphorylation level of MLC 20 ( Fig. 4b and d) as well as vascular contraction (Fig. 4a and c) induced by NaF or U46619 in endothelium-denuded rat aortic rings.
Inhibitory effect of GA on NaF-or U46619-induced RhoA activation
In order to determine whether GA inhibits RhoA/Rhokinase pathway, we measured the level of guanosine triphosphate (GTP) RhoA. NaF or U46619 increased the level of GTP RhoA (2.28±0.15-fold or 2.42±0.17-fold) as compared with the basal level in endothelium-denuded aortic rings. As shown in Fig. 5 , GA (0.3 or 1.0 mM) nearly totally suppressed (p<0.05) the level of GTP RhoA induced by NaF or U46619. However, GA itself did not affect basal level of GTP RhoA (data not shown).
Inhibitory effect of GA on NaF-or U46619-induced MYPT1 Thr855 phosphorylation
We determined the level of the phosphorylated MYPT1 Thr855 , a Rho-kinase substrate. NaF-or U46619-stimulated MYPT1 Thr855 phosphorylation increased significantly (2.87±0.43 and 3.10±0.64, respectively) compared with the control. As shown in Fig. 6 , GA (0.3 or 1.0 mM) decreased the phosphorylation level of MYPT1 Thr855 induced by NaF (1.59±0.17 and 1.04±0.12, respectively) or U46619 (1.48±0.20 and 0.87±0.26, respectively).
Inhibitory effect of GA on NaF-or U46619-induced CPI17 Thr38 phosphorylation
The phosphorylation level of CPI17 Thr38 , another downstream effector of Rho-kinase, was measured. NaF or U46619 increased the phosphorylation level of CPI17 Thr38 (Fig. 8a) . Pretreatment with Ro31-8220, but not with GA, inhibited the vascular contractility and phosphorylation of CPI17 Thr38 in response to PDBu (Fig. 8a and b) .
Discussion
This study demonstrates that GA attenuates vascular contraction through inhibition the RhoA/Rho-kinase signaling pathway. GA decreases the activation of RhoA and subsequent Rho-kinase-dependent phosphorylation of MYPT1 Thr855 and CPI17 Thr38 . GA also inhibited the phosphorylation of MLC 20 and the contraction in denuded rat aortic rings. However, GA did not affect K + channels or PKC pathway during vascular relaxation.
The small GTPase RhoA plays an important role as a molecular switch in the enhancement of Ca 2+ sensitivity of smooth muscle contraction (Kawano et al. 2002) . Activation of receptors coupled to trimeric G proteins (G α12,13 ) leads through the activity of guanine nucleotide exchange factors (GEFs) to the exchange of GTP for GDP on RhoA. GTP RhoA translocates to the plasma membrane, where it interacts with Rho-kinase to initiate signaling cascades. When Rho GTPase-activating proteins (RhoGAPs) catalyze hydrolysis of GTP bound to RhoA, GDP RhoA reassociates with RhoGDI (Somlyo and Somlyo 2003) . NaF activate RhoA through activation of G proteins (Antonny et al. 1993) . Furthemore, NaF binds and inhibits RhoGAPs, thereby resulting in Rho activation (Vincent and Settleman 1999) . U46619 activates GEF upon binding to the thromboxane A 2 receptor which is coupled to G 12/13 (Wilson et al. 2005 ). The present study showed that NaF and U46619 activated RhoA approximately 2.3-fold and 2.4-fold over the resting level, respectively (Fig. 5) . These data are consistent with previous reports in which NaF or U46619 activated RhoA (Seok et al. 2008; Yang et al. 2009 ). Furthermore, GA reduced the activation of the RhoA induced by NaF or U46619 (Fig. 5) . GA may suppress GTP RhoA activation, through interaction with GEFs, RhoGAPs, or RhoGDI.
The activity of myosin phosphatase decreases when PKC-potentiated inhibitory protein for heterotrimeric MLCP of 17 kDa (CPI17) or MYPT1 is phosphorylated (Feng et al. 1999) . MLCP is a heterotrimer consisting of a catalytic subunit PPIcδ, a 130-kDa regulatory subunit MYPT1 and a 20-kDa subunit of unknown function (Hartshorne et al. 1998) . We examined the level of phosphorylated MYPT1 Thr855 , which is an inhibitory site and is phosphorylated by the Rho-kinase. Activation of Rho-kinase by U46619 or phenylephrine, an α1-adrenergic agonist, phosphorylates MYPT1 at Thr855, but not MYPT1 at Thr697 (Tsai and Jiang 2006; Wilson et al. 2005) . The phosphorylation of MYPT1 Thr697 is independent of the stimulation of G proteins, Rho-kinase, or PKC (Kitazawa et al. 2003; Niiro et al. 2003) . We observed that GA inhibited MYPT1 Thr855 phosphorylation induced by U46619 or NaF (Fig. 6 ). These observations suggest that GA inhibits the phosphorylation of MYPT1 Thr855 induced by Rho-kinase.
CPI17 is another downstream effector of Rho-kinase, which was first isolated from porcine aorta and identified as a substrate of PKC at Thr38 (Eto et al. 1995) . U46619-induced CPI17 Thr38 phosphorylation was abolished by a Rho-kinase inhibitor Y27632, suggesting that Rho-kinase is involved in U46619-induced CPI17 phosphorylation and contractions (Pang et al. 2005) . These reports showed that U46619 caused CPI17 phosphorylation through activation of the RhoA/Rho-kinase pathway, whereas PDBu phosphorylates CPI17 through direct activation of protein kinase C pathway. In a separate study of our laboratory, activation of Rho-kinase by NaF, or U46619 phosphorylates CPI17 Thr38 (Seok et al. 2008; Yang et al. 2009 ). Our data also showed that NaF or U46619 significantly increased CPI17 Thr38 phosphorylation, which was inhibited by GA (Fig. 7) . However, PDBu-induced CPI17 Thr38 phosphorylation was not inhibited by GA (Fig. 8b) .
It is well known that K + channels play an important role in the regulation of muscle contractility and vascular tone. Because K + channels are the dominant ion conductive pathway in vascular smooth muscle, inhibition of K + channels lead to membrane depolarization and vascular contraction (Jackson 2000; Nelson and Quayle 1995; Standen and Quayle 1998) . However, in our experiment (Fig. 3) , the relaxant action of GA in the rat aorta did not seem to be due to the opening of K + channels, since the vasorelaxant effects of GA were unaffected by pretreatment with glibenclamide (a blocker of ATP-sensitive K + channels), apamin (a blocker of small-conductance Ca 2+ -activated K + channels) and charybdotoxin (a blocker of large-conductance Ca 2+ -activated K + channels). These data are in accordance with previous report that vasorelaxant action of S. chinensis extracts was unaffected by tetraethylammonium, a nonselective blocker of K + channels (Park et al. 2009b) . Smooth muscle contraction is mainly regulated by the level of phosphorylation of MLC 20 , which is determined by the opposing action of myosin light-chain kinase (MLCK) and MLCP. MLCK mediates MLC phosphorylation causing contraction in a Ca 2+ /calmodulin-dependent manner (Kamm and Stull 1985) . Conversely, MLCP mediates dephosphorylation of phosphorylated MLC causing relaxation (Bialojan et al. 1987; Somlyo and Somlyo 1994) . Furthermore, activation of Rho-kinase by NaF or U46619 inhibits the activity of MLCP through phosphorylation of regulatory MYPT1 Thr855 , leading to an increased MLC 20 phosphorylation and contraction (Wang et al. 2001; Wilson et al. 2005; Yang et al. 2009 ). In the present study, GA reduced not only vascular contraction but also the phosphorylation of MLC 20 induced by NaF or U46619 in endothelium-denuded rat aortic rings (Fig. 4) . GA inhibited concentraction-response curves to U46619 and to NaF in endothelium-denuded aortic rings. This result is in accordance with the finding that GA decreased vascular contraction and MLC 20 phosphorylation induced by phenylephrine and that ML 9, an inhibitor of MLCK, failed to modify GA-induced relaxation. These data suggest that the vasorelaxation by GA is mediated by dephosphorylation of phosphorylated MLC through activation of MLCP (Park et al. 2007) .
A dozen of years ago, the Rho-kinase was identified to be involved in development of high blood pressure (Uehata et al. 1997) . Rho-kinase has been identified as an important target for treatment of several cardiovascular diseases (Budzyn et al. 2006; Lohn et al. 2009 ). GA decreased vascular contraction induced by NaF or U46619 through inhibition of the RhoA/Rho-kinase pathway. Therefore, GA may be a potential lead for development of therapeutic drugs. Although GA induces not only endotheliumdependent but also endothelium-independent vascular relaxation in isolated thoracic aorta (Park et al. 2007; Rhyu et al. 2006) , GA may have a main action through activation of NO pathway in endothelium. However, in some instances such as endothelial dysfunction, it may exert endothelium-independent vascular relaxation through activation of RhoA/Rho-kinase signaling pathway which inhibits MLC phosphatase.
In conclusion, GA directly relaxes NaF-and U46619-, but not PDBu-induced vascular contraction in the absence of endothelium. These results suggest that GA attenuates vascular contractions through the inhibition of the RhoA/ Rho-kinase pathway. However, K + channels are not involved in the vascular relaxation induced by GA.
